secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2021-09-09T23:59:59+00:00
Accession:  0000950170-21-001745
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics appoints Ronald Barrett and Alana McNulty as directors
-------------------------------------------------------------------------

- Ronald Barrett, Ph.D. appointed as Class I director with term expiring at 2022 annual meeting.
- Alana McNulty appointed as Class II director with term expiring at 2023 annual meeting.
- Each receives $40,000 annual cash retainer and option to purchase 30,000 shares vesting over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017021001745/0000950170-21-001745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017021001745/janx-20210907.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer